Anna-Lena Gustavsson

Platform Director: Chemical Biology and Genome Engineering, Karolinska Institutet

Head of Unit: Chemical Biology Consortium Sweden

Key publications

Giovannucci et.al; Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound. Cell Death Dis. 12 (10) 914 [2021-10-06; online 2021-10-06]
Rendo et.al; Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nat Commun 11 (1) – [2020-12-00; online 2020-03-11]
Ladds et.al; A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Comm. 2018, 9, 1107.

I have a Ph.D. in organic chemistry and over a decade of expertise in drug discovery research within the pharmaceutical industry, both as an expert in computational chemistry and as a manager/project team leader. In 2010, I was co-founding the Chemical Biology Consortium Sweden (CBCS); a national research infrastructure in chemical biology providing expertise in assay development and small molecule screening, and follow up medicinal/computational chemistry support for academic researchers in Sweden, (www.cbcs.se).

Since 2017 I has been the managing director of this national research infrastructure. Based on funding from the Swedish research council, CBCS is a distributed and coordinated infrastructure with activities at six universities around Sweden with a running budget of about 40 MSEK and 24 full-time employees supporting approximately 50 research groups per year.

Together with the Crispr Functional Genomics unit and the Chemical Proteomics unit, CBCS creates a unique multidisciplinary platform at the Science for Life Laboratory.

Group Members:

Hanna Axelsson
Francesco Massai
Kun QIan
Bartlomiej Porebski
Martin Haraldsson
Tobias Koolmeister
Michaela Vallin
Flavio Ballante
Bruna Clemens
Mats Dahlberg
Åsa Slevin
Maria Adolfsson
Elisabeth Olsson

Last updated: 2025-01-14

Content Responsible: Johan Inganni(johan.inganni@scilifelab.se)